Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesized that dornase alpha, administered twice a day (BID) by in-line nebulizer, would improve oxygenation, compliance, and time to extubation in adult patients receiving mechanical ventilation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Medicine and Dentistry of New Jersey

Criteria

Inclusion Criteria:

• current ventilator use

• onset of lobar or whole lung collapse over the previous 12 hours

• age greater than 18

Exclusion Criteria:

• quadriplegia or debilitating neuromuscular condition

• chronic ventilator dependence

• pneumothorax

• frank hemoptysis

• elevated intracranial pressure

• intracranial bleed

• pregnancy or active nursing

• concurrent use of other investigational drugs

• history of allergy to Pulmozyme®, Chinese Hamster Ovary-derived biologics, or any of the components of the active or placebo formulations.